3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
2
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Follicular
10
Lymphoma
9
Lymphoma, Mantle-Cell
8
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, B-Cell
4
Recurrence
3
Lymphoma, Non-Hodgkin
3
Waldenstrom Macroglobulinemia
2
Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Hodgkin Disease
2
Proteostasis Deficiencies
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Immunoglobulin Light-chain Amyloidosis
1
Immunoblastic Lymphadenopathy
1
Hematopoietic and Lymphoid System Neoplasm
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Surveys and Questionnaires
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
Bendamustine Hydrochloride
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled